Want to join the conversation?
$ONCE and $PFE said FDA granted breakthrough therapy designation to SPK-9001, which is being investigated in ongoing Phase 1/2 trial as potential one-time therapy, to treat rare genetic bleeding disorder hemophilia B. The designation is intended to expedite development and FDA review of drugs to treat serious or life-threatening disease.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.